Notice of special administration instructions for Zemaira. Read more here X


You may be wondering about alpha-1 antitrypsin deficiency symptoms,
or Alpha-1, and what happens next. It is natural to have questions.

What is Alpha-1?

Alpha-1 is a hereditary condition marked by a shortage of a functional protein known as alpha-1 antitrypsin.1

  • Alpha-1 antitrypsin plays an important role in protecting your lungs from damage due to excessive inflammation.
  • Without this protein, your lungs may weaken over time and place you at a higher risk for developing diseases, such as emphysema and chronic obstructive pulmonary disease (COPD).

Hear more from an Alpha-1 expert.

Do I have Alpha-1?

Take the Alpha-1 Questionnaire and learn more

This brief questionnaire can help you understand your chances for having Alpha-1. Be aware that your answers are completely confidential—there is no sign-in required.

Important Safety Information

Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated to raise the plasma level of alpha1-proteinase inhibitor (A1-PI) in patients with A1-PI deficiency and related emphysema. The effect of this raised level on the frequency of pulmonary exacerbations and the progression of emphysema have not been established in clinical trials.

Zemaira may not be suitable for everyone; for example, people with known hypersensitivity to components used to make Zemaira, those with a history of anaphylaxis or severe systemic response to A1-PI products, and those with certain IgA deficiencies. If you think any of these may apply to you, ask your doctor.

Early signs of hypersensitivity reactions to Zemaira include hives, rash, tightness of the chest, unusual breathing difficulty, wheezing, and feeling faint. Immediately discontinue use and consult with physician if such symptoms occur.

In clinical studies, the following adverse reactions were reported in at least 5% of subjects receiving Zemaira: headache, sinusitis, upper respiratory infection, bronchitis, fatigue, increased cough, fever, injection-site bleeding, nasal symptoms, sore throat, and swelled blood vessels.

Because Zemaira is made from human blood, the risk of transmitting infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information for Zemaira.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.

Zemaira is manufactured and distributed by CSL Behring LLC.
Zemaira® and CareZ® are registered trademarks of CSL Behring LLC.

© 2018 CSL Behring LLC. The product information presented on this site is intended for US residents only. ZMR03-13-0022(3) 6/2015